Literature DB >> 12681366

Expression of serologically identified tumor antigens in acute leukemias.

Philipp Niemeyer1, Ozlem Türeci, Thomas Eberle, Norbert Graf, Michael Pfreundschuh, Ugur Sahin.   

Abstract

Cancer/testis antigens (CTA) are an expanding family of immunogenic proteins selectively expressed in human neoplasms. As little is known about the expression of serologically identified CTA in leukemias so far, we investigated the expression of 5 CT genes (SSX-1, HOM-MEL-40/SSX-2, HOM-TES-14/SCP-1, SCP-3 and NY-ESO-1) in leukemic blood samples obtained from patients with either acute lymphatic leukemias (ALL) or myelocytic leukemia (AML). RT-PCR-analyses showed no expression of any of the CT-genes in the leukemia samples of 19 patients with AML, whereas frequent expression was found in ALL. In the 17 ALL cases studied, SCP3a, SSX-1, HOM-MEL-40/SXX-2 and HOM-TES-14/SCP-1 were expressed in 47, 29, 29 and 12%, respectively, whereas no case was positive for NY-ESO-1. 65% of patients with ALL showed expression of at least one, 41% of two or more of the five CT-genes investigated. We conclude that a majority of the ALLs might be amenable for specific immunotherapeutic interventions. However, the identification of additional antigens with a frequent expression in leukemias is warranted to allow the development of widely applicable polyvalent leukemia vaccines.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12681366     DOI: 10.1016/s0145-2126(02)00230-8

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  14 in total

1.  Scp3 expression in relation to the ovarian differentiation in the protogynous hermaphroditic ricefield eel Monopterus albus.

Authors:  Yixue Li; Zhi He; Shuxia Shi; Yize Zhang; Dong Chen; Weimin Zhang; Lihong Zhang
Journal:  Fish Physiol Biochem       Date:  2016-06-08       Impact factor: 2.794

Review 2.  Vaccines as consolidation therapy for myeloid leukemia.

Authors:  Gheath Alatrash; Jeffrey J Molldrem
Journal:  Expert Rev Hematol       Date:  2011-02       Impact factor: 2.929

3.  Synaptonemal complex protein 3 as a novel prognostic marker in early stage non-small cell lung cancer.

Authors:  Joon-Yong Chung; Haruhisa Kitano; Mikiko Takikita; Hanbyoul Cho; Kyung Hee Noh; Tae Woo Kim; Kris Ylaya; Jun Hanaoka; Junya Fukuoka; Stephen M Hewitt
Journal:  Hum Pathol       Date:  2012-10-12       Impact factor: 3.466

4.  Deficiency in the multicopy Sycp3-like X-linked genes Slx and Slxl1 causes major defects in spermatid differentiation.

Authors:  Julie Cocquet; Peter J I Ellis; Yasuhiro Yamauchi; Jonathan M Riel; Thomas P S Karacs; Aine Rattigan; Obah A Ojarikre; Nabeel A Affara; Monika A Ward; Paul S Burgoyne
Journal:  Mol Biol Cell       Date:  2010-08-25       Impact factor: 4.138

Review 5.  The SSX family of cancer-testis antigens as target proteins for tumor therapy.

Authors:  Heath A Smith; Douglas G McNeel
Journal:  Clin Dev Immunol       Date:  2010-10-11

6.  The ectopic expression of meiCT genes promotes meiomitosis and may facilitate carcinogenesis.

Authors:  Jennifer Gantchev; Amelia Martínez Villarreal; Scott Gunn; Monique Zetka; Neils Ødum; Ivan V Litvinov
Journal:  Cell Cycle       Date:  2020-03-30       Impact factor: 4.534

7.  Synaptonemal complex protein SYCP3 impairs mitotic recombination by interfering with BRCA2.

Authors:  Noriko Hosoya; Miyuki Okajima; Aiko Kinomura; Yoshihiro Fujii; Takashi Hiyama; Jiying Sun; Satoshi Tashiro; Kiyoshi Miyagawa
Journal:  EMBO Rep       Date:  2011-12-23       Impact factor: 8.807

8.  Synaptonemal complex protein 3 is a prognostic marker in cervical cancer.

Authors:  Hanbyoul Cho; Kyung Hee Noh; Joon-Yong Chung; Mikiko Takikita; Eun Joo Chung; Bo Wook Kim; Stephen M Hewitt; Tae Woo Kim; Jae-Hoon Kim
Journal:  PLoS One       Date:  2014-06-06       Impact factor: 3.240

Review 9.  Ectopic Expression of Testis Germ Cell Proteins in Cancer and Its Potential Role in Genomic Instability.

Authors:  Aaraby Yoheswaran Nielsen; Morten Frier Gjerstorff
Journal:  Int J Mol Sci       Date:  2016-06-06       Impact factor: 5.923

Review 10.  Novel approaches to immunotherapy for B-cell malignancies.

Authors:  Renier J Brentjens
Journal:  Curr Oncol Rep       Date:  2004-09       Impact factor: 5.945

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.